✦ LIBER ✦

Safety, tolerability and efficacy of lecozotan SR in patients with mild-to-moderate Alzheimer's disease used as monotherapy or adjunctively with a cholinesterase inhibitor

✍ Scribed by Booth, Kevin; Zhao, Yonggang; Hua, Yue; Wilks, Kerri; Solomon, Paul; Lucas, Prisca; Murray, Ermellina; Raje, Sangeeta; Black, Ronald S.

Book ID: 123297480
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 53 KB
Volume: 8
Category: Article
ISSN: 1552-5260
DOI: 10.1016/j.jalz.2012.05.2099

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A long-term, double-blind, placebo-contr

A long-term, double-blind, placebo-controlled efficacy and safety study of nicergoline in patients with mild to moderate Alzheimer's disease

✍ L. Amaducci; K. Maurer; B. Winblad; R. Dom; R. Bullock; L. Bonura; A. Battaglia; 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 291 KB

Efficacy and Safety of Intravenous Solan

Efficacy and Safety of Intravenous Solanezumab in Patients with Mild to Moderate Alzheimer's Disease: Results of Two Phase 3 Studies

✍ Hake, Ann M.; Siemers, Eric; Carlson, Christopher; Estergard, Wahiba; Sundell, K 📂 Article 📅 2013 🏛 American Psychiatric Publishing Inc 🌐 English ⚖ 50 KB

P.5.a.006 Long-term safety and tolerabil

P.5.a.006 Long-term safety and tolerability of memantine: an open-label extension study in patients with mild to moderate Alzheimer's disease

✍ S. Bakchine; M. Rainer 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 55 KB

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONT

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CRENEZUMAB IN PATIENTS WITH MILD TO MODERATE ALZHEIMER'S DISEASE

✍ Cummings, Jeffrey; Cho, William; Ward, Michael; Friesenhahn, Michel; Brunstein, 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 51 KB

Safety, tolerability, and preliminary ef

Safety, tolerability, and preliminary efficacy of SAM-531, a 5HT-6 antagonist, in subjects with mild-to-moderate Alzheimer's disease: Results from a phase 2a study

✍ Claudine Brisard; Beth Safirstein; Kevin Booth; Lisa Hua; Yves Brault; Sangeeta 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 43 KB

A multicentre, randomized, double-blind,

A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study

✍ Bruno Dubois; Ian McKeith; Jean-Marc Orgogozo; Owen Collins; Didier Meulien 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB 👁 3 views

Background. Metrifonate is a long-lasting acetylcholinesterase inhibitor being developed for the symptomatic treatment of Alzheimer's disease (AD). Objectives. This study compared the ecacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate AD, over a 26-week tre